Holen Sie sich die Stockscreener-App
4.21
1.20%
0.05
Schlusskurs vom Vortag:
$4.16
Offen:
$4.21
24-Stunden-Volumen:
31,219
Relative Volume:
0.24
Marktkapitalisierung:
$242.47M
Einnahmen:
$34.16M
Nettoeinkommen (Verlust:
$-98.43M
KGV:
-1.7991
EPS:
-2.34
Netto-Cashflow:
$-119.33M
1W Leistung:
-3.44%
1M Leistung:
+23.10%
6M Leistung:
-49.28%
1J Leistung:
-31.10%
1-Tages-Spanne:
$4.08
$4.30
1-Wochen-Bereich:
$4.00
$4.51
52-Wochen-Spanne:
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Vergleichen Sie FHTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.24 | 242.47M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.18 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.70 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
652.21 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.75 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.18 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India
Foghorn Therapeutics expands board with biotech veterans - Investing.com
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire Inc.
Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus
Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus
Foghorn Therapeutics Presents Preclinical Data at AACR 2025 - TipRanks
Foghorn Therapeutics Presents New Preclinical Data on - GlobeNewswire
Breakthrough Cancer Drug FHD-909 Shows Synergy with Leading Treatments in Lung Cancer Studies - Stock Titan
Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at JMP Securities - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Earns Mkt Outperform Rating from Analysts at Citizens Jmp - Defense World
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation - Nasdaq
Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Targ - GuruFocus
Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Target | FHTX Stock News - GuruFocus
Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World
Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | FHTX Stock News - GuruFocus
Foghorn Therapeutics to Host Virtual Investor Event to - GlobeNewswire
Major Pipeline Breakthrough: Foghorn's First-in-Class Cancer Drug Shows Promise in NSCLC Treatment - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Wellington Management Group LLP - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Trading 4.1% Higher – Time to Buy? - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely - simplywall.st
(FHTX) Technical Data - news.stocktradersdaily.com
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients (NASDAQ:FHTX) - Seeking Alpha
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - The AM Reporter
Foghorn Therapeutics Announces New Preclinical Data for - GlobeNewswire
Breakthrough Cancer Drug FHD-909 Reveals Powerful Combination Potential Against Lung Cancer - Stock Titan
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World
2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc. - Defense World
Foghorn Therapeutics adjusts ATM offering to $100M By Investing.com - Investing.com Australia
Foghorn Therapeutics adjusts ATM offering to $100M - Investing.com
Research Analysts Offer Predictions for FHTX Q1 Earnings - The AM Reporter
What is B. Riley’s Forecast for FHTX Q1 Earnings? - Defense World
Foghorn Therapeutics Reports Progress and Financial Stability - TipRanks
Rhumbline Advisers Purchases 3,049 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics’ (FHTX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy - TipRanks
Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances - TipRanks
Foghorn Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late - Marketscreener.com
Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook - Nasdaq
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - GlobeNewswire
Can Foghorn's $243M War Chest Transform Cancer Treatment? Key Pipeline Updates - StockTitan
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo
Foghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on Thursday - Defense World
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.01%
2.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):